# **ModernGraham Valuation**

## **Company Name:**

**Abbott Laboratories** 



Company Ticker ABT

Date of Analysis 2/28/2019

### Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$136,723,618,367 Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	1.62 Fail
3. Earnings Stability	Positive EPS for 10 years prior	Pass
4. Dividend Record	Dividend Payments for 10 years prior	Pass
	Increase of 33% in EPS in past 10 years using 3 year averages at	
5. Earnings Growth	beginning and end	-50.67% Fail
6. Moderate PEmg Ratio	PEmg < 20	43.49 Fail
7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	4.49 Fail

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	1.62	Pass
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	3.44	Fail
3. Earnings Stability	Positive EPS for 5 years prior		Pass
Dividend Record	Currently Pays Dividend		Pass
5. Earnings Growth	EPSmg greater than 5 years ago		Fail

Score

Suitability

Defensive No Enterprising No

#### Stage 2: Determination of Intrinsic Value

EPSmg	\$1.79
MG Growth Estimate	-3.78%
MG Value	\$1.68
MG Value based on 3% Growth	\$25.94
MG Value based on 0% Growth	\$15.20
Market Implied Growth Rate	17.50%

MG Opinion

**Current Price** \$77.79 % of Intrinsic Value 4629.78%

Opinion Overvalued MG Grade


#### Stage 3: Information for Further Research

Net Current Asset Value (NCAV)	-\$12.30
Graham Number	\$35.26
PEmg	43.49
Current Ratio	1.62
PB Ratio	4.49
Current Dividend	\$1.12
Dividend Yield	1.44%
Number of Consecutive Years of Dividend	
Growth	5

**Useful Links:** ModernGraham tagged articles

Morningstar Google Finance MSN Money Yahoo Finance Seeking Alpha **GuruFocus** SEC Filings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate	*****	Next Fiscal Year Estimate	\$1.79
Dec2018	\$1.33	Dec2018	\$1.19
Dec2017	\$0.27	Dec2017	\$1.23
Dec2016	\$0.94	Dec2016	\$1.85
Dec2015	\$2.92	Dec2015	\$2.39
Dec2014	\$1.49	Dec2014	\$2.27
Dec2013	\$1.62	Dec2013	\$2.77
Dec2012	\$3.72	Dec2012	\$3.33
Dec2011	\$3.01	Dec2011	\$3.10
Dec2010	\$2.96	Dec2010	\$2.98
Dec2009	\$3.69	Dec2009	\$2.82
Dec2008	\$3.12	Dec2008	\$2.31
Dec2007	\$2.31	Dec2007	\$1.89
Dec2006	\$1.12	Dec2006	\$1.71
Dec2005	\$2.16	Dec2005	\$1.92
Dec2004	\$2.06	Dec2004	\$1.76
Dec2003	\$1.75	Dec2003	\$1.60
Dec2002	\$1.78	Balance Sheet Information	12/1/2018
Dec2001	\$0.99	Total Current Assets	\$14,632,000,000
Dec2000	\$1.78	Total Current Liabilities	\$9,012,000,000
Dec1999	\$1.57	Long-Term Debt	\$19,359,000,000
		Total Assets	\$67,173,000,000
		Intangible Assets	\$42,196,000,000
		Total Liabilities	\$36,451,000,000
		Shares Outstanding (Diluted Average)	1,773,870,000





#### Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

#### **Recommended Reading:**

Other ModernGraham posts about the company 10 Most Overvalued Stocks of the S&P 500 – July 2018
Abbott Laboratories Valuation – May 2018 \$ABT
Abbott Laboratories Valuation – January 2017 \$ABT
Abbott Laboratories Valuation – August 2016 \$ABT

5 Speculative and Overvalued Companies to Avoid - March 2015

Other ModernGraham posts about related companies Becton Dickinson and Co Valuation – February 2019 \$BDX IQVIA Holdings Inc Valuation – February 2019 \$IQV Thermo Fisher Scientific Inc Valuation – February 2019 \$TMO

Illumina Inc Valuation – February 2019 \$ILMN
Waters Corp Valuation – February 2019 \$WAT

<u>Cerner Corp Valuation – February 2019 \$CERN</u> <u>HCA Healthcare Inc Valuation – February 2019 \$HCA</u>

Stryker Corp Valuation – February 2019 \$SYK

Align Technology Inc Valuation – February 2019 \$ALGN Quest Diagnostics Inc Valuation – February 2019 \$DGX